Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh (950210) Financial Statements

― Followers

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh Financial Overview

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh's market cap is currently ₩303.49B. The company's EPS TTM is ₩-1541.66; its P/E ratio is -3.26; Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh is scheduled to report earnings on September 22, 2026, and the estimated EPS forecast is ₩―. See an overview of income statement, balance sheet, and cash flow financials.

	Jun 25	Jun 25	Jun 23	Jun 22	Jun 22
Income Statement
Total Revenue	₩ 14.31B	₩ 26.06B	₩ 689.08M	₩ 0.00	₩ 161.84M
Gross Profit	₩ -24.01B	₩ -16.36B	₩ -528.79M	₩ -3.87B	₩ 127.90M
Operating Income	₩ -67.28B	₩ -93.58B	₩ -62.78B	₩ -118.82B	₩ 1.03B
EBITDA	₩ 33.31B	₩ -60.84B	₩ -31.06B	₩ -206.91B	₩ 10.50B
Net Income	₩ 22.27B	₩ -91.47B	₩ -32.92B	₩ -211.45B	₩ 17.57B
Balance Sheet
Cash & Short-Term Investments	₩ 173.71B	₩ 63.01B	₩ 228.81B	₩ 303.27B	₩ 301.41B
Total Assets	₩ 741.92B	₩ 741.41B	₩ 711.72B	₩ 499.81B	₩ 741.60B
Total Debt	₩ 144.18B	₩ 106.11B	₩ 89.67B	₩ 4.25B	₩ 86.18B
Net Debt	₩ 28.66B	₩ 89.55B	₩ -129.77B	₩ -264.40B	₩ -38.85B
Total Liabilities	₩ 236.15B	₩ 234.46B	₩ 196.22B	₩ 69.88B	₩ 195.37B
Stockholders' Equity	₩ 408.95B	₩ 434.21B	₩ 439.09B	₩ 429.94B	₩ 450.51B
Cash Flow
Free Cash Flow	₩ -95.04B	₩ -62.48B	₩ -76.02B	₩ -114.02B	₩ -125.89B
Operating Cash Flow	₩ -54.34B	₩ -56.51B	₩ -48.03B	₩ -45.91B	₩ -60.27B
Investing Cash Flow	₩ -99.43B	₩ 42.70B	₩ 132.46B	₩ -184.69B	₩ -148.61B
Financing Cash Flow	₩ 49.81B	₩ -50.80B	₩ -1.46B	₩ -4.50B	₩ 53.18B

Currency in KRW

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh Earnings and Revenue History

Income Statement >

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh Debt to Assets

Balance Sheet >

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh Cash Flow

Cash Flow >

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh Forecast EPS vs Actual EPS

Earnings >